| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 239.675 | 223.949 | 233.200 | 292.470 | 250.261 | 114.534 | 280.680 | 329.359 | 155.387 | 254.240 |
| Total Income - EUR | 242.150 | 299.270 | 284.042 | 246.925 | 280.542 | 384.655 | 194.667 | 381.155 | 173.910 | 368.039 |
| Total Expenses - EUR | 193.321 | 285.402 | 286.553 | 211.963 | 254.550 | 383.754 | 190.127 | 365.344 | 434.128 | 302.568 |
| Gross Profit/Loss - EUR | 48.829 | 13.868 | -2.512 | 34.962 | 25.992 | 901 | 4.540 | 15.811 | -260.218 | 65.471 |
| Net Profit/Loss - EUR | 42.876 | 13.868 | -14.817 | 32.283 | 23.734 | 281 | 3.102 | 11.589 | -261.953 | 56.456 |
| Employees | 5 | 5 | 4 | 2 | 3 | 2 | 2 | 2 | 2 | 3 |
Check the financial reports for the company - Xelaliv S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 60.334 | 251.059 | 167.247 | 109.868 | 133.363 | 92.310 | 76.158 | 107.294 | 106.917 | 186.705 |
| Current Assets | 62.077 | 149.079 | 155.678 | 112.379 | 172.033 | 219.443 | 169.021 | 154.215 | 64.561 | 82.228 |
| Inventories | 11.060 | 68.503 | 63.800 | 14.000 | 39.897 | 149.176 | 60.462 | 55.674 | 28.103 | 45.914 |
| Receivables | 33.572 | 31.628 | 23.264 | 122.479 | 126.084 | 62.636 | 98.521 | 93.827 | 30.604 | 32.775 |
| Cash | 17.446 | 48.949 | 68.614 | -24.100 | 6.053 | 7.630 | 10.039 | 4.715 | 5.854 | 3.539 |
| Shareholders Funds | 55.240 | 54.471 | 17.586 | 45.537 | 31.102 | 18.154 | 24.544 | 6.995 | -262.648 | -208.762 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 67.171 | 345.668 | 305.340 | 176.710 | 274.294 | 293.599 | 220.635 | 254.515 | 434.126 | 477.695 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "111 - 111" | |||||||||
| CAEN Financial Year |
111
|
|||||||||
Comments - Xelaliv S.r.l.